Hepatic Steatosis Clinical Trials

9 recruiting

Hepatic Steatosis Trials at a Glance

9 actively recruiting trials for hepatic steatosis are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Aurora, Boardman, and Chongqing. Lead sponsors running hepatic steatosis studies include Chongqing Medical University, Duke University, and AdventHealth Translational Research Institute.

Browse hepatic steatosis trials by phase

Treatments under study

About Hepatic Steatosis Clinical Trials

Looking for clinical trials for Hepatic Steatosis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatic Steatosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatic Steatosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Not Applicable

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

Type 2 DiabetesHepatic Steatosis
AdventHealth Translational Research Institute12 enrolled1 locationNCT06993454
Recruiting
Not Applicable

Siemens Biomarker Multi-modality

Fatty LiverHepatic Steatosis
Duke University45 enrolled1 locationNCT07495332
Recruiting
Phase 1

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

Healthy VolunteersHepatic Steatosis
Novo Nordisk A/S48 enrolled1 locationNCT06891365
Recruiting

Incidence of Liver Disease-Related Outcomes in People With HIV

Liver FibrosisHIVHepatic Steatosis+3 more
Shanghai Public Health Clinical Center320 enrolled2 locationsNCT06940375
Recruiting
Not Applicable

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

Metabolic Dysfunction-Associated Steatotic Liver DiseaseHepatic SteatosisLiver Disease Parenchymal
Seoul National University Hospital62 enrolled2 locationsNCT07192159
Recruiting
Phase 3

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

NAFLDHepatic SteatosisAdolescent Obesity
University of Colorado, Denver55 enrolled1 locationNCT05935826
Recruiting

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

Liver FibrosisHepatic SteatosisMetabolic Dysfunction-associated Fatty Liver Disease
Chongqing Medical University7,000 enrolled1 locationNCT05974904
Recruiting

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Diabetes MellitusInsulin Sensitivity/ResistanceObesity+16 more
Osaka Metropolitan University2,000 enrolled1 locationNCT06694012
Recruiting
Phase 2

Soluble Fibre Supplementation in NAFLD

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisHepatic Steatosis
McMaster University60 enrolled1 locationNCT05480696